Filipp Korentsvit
Co-Founder and Chief Executive OfficerFilipp leads strategy and the development of Micelle 60 and its access platform.
About Micelle Therapeutics.
We are developing Micelle 60 and building the public records that will accompany each released lot. NW Micelle Therapeutics, Inc. is part of the NW PharmaTech group; Micelle Therapeutics is its trading name.
Every bottle has a page.
The company
One product in development, clearly documented.
Micelle 60 is being developed with NW PharmaTech’s formulation, supply-chain and quality experience. It is a distinct product with its own formulation, specification and evidence.
NW PharmaTech's experience includes developing a separate investigational oral CBD softgel. That program does not establish manufacturing, stability or laboratory evidence for Micelle 60. Micelle 60 remains in development; its own certificates and lot records will be published here with the first released lot.
Read about NW PharmaTech's separate investigational program (opens an external website)
NW PharmaTech groupMicelle Therapeutics is the trading name of NW Micelle Therapeutics, Inc.
The team
The people responsible.
Daud Gutseriev
Co-Founder and Chief Operating OfficerDaud leads operations and the implementation work with care organizations.
Dr Grace Blest-Hopley
Partner and Chief Scientific OfficerDr Grace Blest-Hopley is listed by NW PharmaTech as Partner and Chief Scientific Officer.
For questions about your own health, please contact your care team.
Governance and contact
Accountability before release.
Filipp Korentsvit leads company and program accountability. Daud Gutseriev leads operations and the work to confirm the independent laboratory, quality and regulatory contact, and dedicated concern route before first release.
Current scientific leadership
Dr Grace Blest-Hopley, Partner and Chief Scientific Officer.
Quality and regulatory accountabilityThe named contact will be published before first release after the appointment is documented.
See dated readiness actions